LDN-193189 (dihydrochloride)

LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].

Product Specifications

CAS Number

[1435934-00-1]

Product Name Alternative

DM-3189 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Organoid; TGF-β Receptor

Type

Reference compound

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ldn-193189-dihydrochloride.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 11.11 mg/mL (ultrasonic)

Smiles

C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16.Cl.Cl

Molecular Formula

C25H24Cl2N6

Molecular Weight

479.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14 (12), 1363-1369.|[2]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290 (6) :3390-404.|[3]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667.